NextCure, Inc.
Clinical trials sponsored by NextCure, Inc., explained in plain language.
Biopharma developing immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New targeted drug LNCB74 enters human trials for Hard-to-Treat cancers Results expected Dec 2026 (estimated)
-
Can a new drug combo revive Immunotherapy's power against resistant tumors?
Disease control Stopped earlyThis trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…
Phase 1/2 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New antibody drug takes on tough blood cancers
Disease control Stopped earlyThis early-stage trial tested a new drug called NC525 in people with advanced myeloid neoplasms, including relapsed or refractory acute myeloid leukemia. The main goal was to check safety and tolerability, with a secondary focus on whether the drug could shrink tumors or improve …
Phase 1 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC